Use of Ambulatory Electrocardiography for the Detection of Paroxysmal Atrial Fibrillation in Patients with Stroke

Chaim Bell, Moira Kapral, with The Canadian Task Force on Preventive Health Care

ABSTRACT: Background: Patients with stroke commonly undergo investigations to determine the underlying cause of stroke. These investigations often include ambulatory electrocardiography to detect paroxysmal atrial fibrillation. There is conflicting evidence in the literature regarding whether routine ambulatory electrocardiography should be performed in all or selected stroke patients. This paper reviews the available evidence on (1) the yield of ambulatory electrocardiography to detect paroxysmal atrial fibrillation in patients with stroke or transient ischemic attack and (2) the effectiveness of anticoagulation in preventing recurrent stroke in patients with paroxysmal atrial fibrillation. Methods: A MEDLINE search for primary articles was performed, and the references were reviewed manually. In addition, citations were obtained from experts. The evidence was systematically reviewed using the evidence-based methodology of the Canadian Task Force on Preventive Health Care. Results: Ambulatory electrocardiography can detect atrial fibrillation not found on initial electrocardiogram in between 1% and 5% of people with stroke. Ambulatory electrocardiography is generally safe. The risk of recurrent stroke in the setting of paroxysmal atrial fibrillation is uncertain, but appears to be similar to that seen with chronic atrial fibrillation (about 12% per year). Therapy with warfarin may reduce this risk by about two-thirds as compared to placebo. The annual risk of major bleeding with warfarin therapy is between 1% and 3% but rates for individual patients depend on various specific risk factors. Interpretation: There is insufficient evidence to recommend for or against the use of ambulatory electrocardiography for the detection of paroxysmal atrial fibrillation in either selected or unselected patients with stroke (B Recommendation). There is fair evidence to recommend therapy with warfarin for patients with stroke and paroxysmal atrial fibrillation (B Recommendation).

RÉSUMÉ: Électrocardiographie ambulatoire pour la détection de la fibrillation auriculaire paroxystique chez les patients ayant subi un AVC. Introduction: Les patients ayant subi un AVC sont couramment investigués pour déterminer la cause de l’AVC. Ces investigations incluent souvent un enregistrement électrocardiographique ambulatoire pour détecter une fibrillation auriculaire paroxystique. Il existe des données conflictuelles dans la littérature concernant l’utilisation de l’électrocardiographie ambulatoire chez tous les patients ayant subi un AVC ou chez des cas particuliers. Nous revoyons les données disponibles sur 1) le taux de détection de la fibrillation auriculaire paroxystique par électrocardiographie ambulatoire chez les patients ayant subi un AVC ou une ischémie transitoire et 2) l’efficacité de l’anticoagulation dans la prévention d’une récidive de l’AVC chez les patients qui ont une fibrillation auriculaire paroxystique. Méthodes: Une recherche d’articles dont c’était le sujet principal dans MEDLINE a été effectuée et les références ont été révisées manuellement. De plus, l’opinion d’experts dans le domaine a été obtenue. Les observations ont été révisées systématiquement en utilisant la méthodologie basée sur des données probantes du Groupe de travail Canadien sur les soins de santé préventifs. Résultats: L’électrocardiographie ambulatoire peut détecter une fibrillation auriculaire qui n’a pas été détectée à l’électrocardiogramme initial chez 1% à 5% des patients ayant subi un AVC. L’électrocardiographie ambulatoire est généralement sécuritaire. Le risque pour le patient de présenter un nouvel AVC dans le contexte de la fibrillation auriculaire paroxystique est incertain, mais il semble identique au risque observé dans la fibrillation auriculaire chronique (environ 12% par année). Le traitement par la warfarine peut diminuer ce risque d’au moins les deux tiers comparé au placebo. Le risque annuel de saignement majeur sous traitement par la warfarine est de 1% à 3%, mais le taux individualisé dépend de différents facteurs de risque spécifiques. Interprétation: Il n’existe pas suffisamment de données pour recommander ou ne pas recommander l’électrocardiographie ambulatoire pour la détection de la fibrillation auriculaire paroxystique chez des patients choisis ou non, ayant subi un AVC (recommandation de catégorie C). Il existe des données suffisantes pour recommander l’administration de warfarine chez les patients qui ont subi un AVC et qui font de la fibrillation auriculaire paroxystique (recommandation de catégorie B).


Stroke is a leading cause of mortality in Canada. It is a common and debilitating condition, particularly in those over age 65. It is responsible for long hospital stays and its survivors often require long-term care placement or assistance with activities of daily living. The cost of acute and long-term care for patients with stroke is estimated at greater than $2.5 billion per year in Canada. Stroke registries and population studies report that cardio-

From the Department of Medicine, University of Toronto, Institute of Medical Science, Program in Clinical Epidemiology and Health Services Research (C.B.) and the Department of Medicine, University of Toronto, Division of General Internal Medicine and Clinical Epidemiology, University Health Network, Toronto, Canada and the Institute for Clinical and Evaluative Sciences (M.K.).


Reprint requests to: C. Bell, Canadian Task Force on Preventive Health Care, 801 Commissioners Rd. East, London, Ontario, N6C 5J1
genic embolism accounts for about 15% (range, 6% to 23%) of ischemic strokes and 15% of transient ischemic attacks.\textsuperscript{5-8} Cardioembolic stroke, which is defined as “the presence of a potential cardioembolic source in the absence of cerebrovascular disease in patients with nonlacunar stroke”, is a heterogeneous entity, comprising multiple contributing disorders. Atrial fibrillation, a common condition found in almost 3% of the population,\textsuperscript{9} accounts for between 6% and 24% of all ischemic strokes and about one half of all cardioembolic strokes.\textsuperscript{5,8,10} The Framingham Study and retrospective reviews have found that paroxysmal or intermittent atrial fibrillation accounts for between 14% and 24% of strokes associated with atrial fibrillation and likely precedes the event.\textsuperscript{11-14} However, there are significant limitations to accurately determining the frequency and establishing the causes of cardioembolic stroke, as no criterion standard exists for its diagnosis. Often, patients will have both cerebrovascular disease and a potential cardioembolic source of emboli, and it may not be possible to determine the true cause of stroke in an individual patient.\textsuperscript{5,15}

The mechanism of stroke should be identified in any individual patient, since the optimal therapy for secondary stroke risk reduction may vary with the underlying cause of stroke.\textsuperscript{5,8,10} Investigations for the cause of stroke typically include a patient history, physical examination, 12-lead electrocardiogram, laboratory tests, computed tomography of the brain, carotid artery imaging, and an echocardiogram (transthoracic or transesophageal). A 24-hour ambulatory continuous electrocardiogram is often obtained to search for an occult arrhythmia, the most common of which is paroxysmal atrial fibrillation. If found, paroxysmal atrial fibrillation may be an indication for treatment with anticoagulant medications to reduce the risk of subsequent stroke.

The evidence for the use of ambulatory continuous electrocardiography to identify a stroke patient with transient or paroxysmal atrial fibrillation that would not have been identified on initial testing will be evaluated in this paper. This manuscript will review and make recommendations regarding the available evidence on (1) the yield of ambulatory continuous electrocardiography in identifying paroxysmal or occult atrial fibrillation in stroke patients, and (2) the effectiveness of therapy for secondary stroke prophylaxis in patients with paroxysmal atrial fibrillation.

**METHODS**

After developing the causal pathway, evidence for each component was identified by an electronic literature search of MEDLINE (1966 to June 1999) using the MeSH terms “cerebrovascular disorders”, “atrial fibrillation”, “electrocardiography, ambulatory”, “electrocardiography”, “monitoring, physiologic”, “diagnosis”, “prevention”, “research design”, “therapy”, “cohort studies”, and “clinical trials”. A professional librarian reviewed the search strategy. A manual review of references cited in these studies was also performed. Citations from experts and guidelines were obtained. Studies published in manuscript or abstract form in peer-reviewed journals were included. Both English and non-English language articles with English abstracts were considered. Studies were included if patients suffered a stroke or transient ischemic attack, had continuous electrocardiography performed, and if the presence or absence of chronic or paroxysmal atrial fibrillation was recorded.

This evidence was systematically reviewed using the methodology of the Canadian Task Force on Preventive Health Care. The Task Force of expert clinician/methodologists from a variety of medical specialties used a standardized evidence-based method for evaluating the effectiveness of this intervention. A manuscript providing critical appraisal of the evidence was prepared by the lead authors. This included identification and critical appraisal of key studies, and ratings of the quality of this evidence using the Task Force’s established methodological hierarchy (Appendix 1), resulting in a summary of proposed conclusions and recommendations for consideration by the Task Force. This manuscript was pre-circulated to the members in April 1998 and evidence for this topic was presented by the lead authors and deliberated upon at a Task Force meeting in May 1998.

At the meeting, the expert panelists addressed critical issues, clarified ambiguous concepts and analysed the synthesis of the evidence. At the end of this process, the specific clinical recommendations proposed by the lead author were discussed, as were issues related to clarification of the recommendations for clinical application, and any gaps in evidence. The results of this process are reflected in the description of the decision criteria presented with the specific recommendations. The final decisions on recommendations were arrived at unanimously by the group and lead authors.

Subsequent to the meeting, the lead authors revised the manuscript accordingly. After final revision, the manuscript was sent by the Task Force to two experts in the field (identified by Task Force members at the meeting). Feedback from these experts was incorporated into a subsequent draft of the manuscript, which was then submitted to this Journal.

Procedures to achieve adequate documentation, consistency, comprehensiveness, objectivity and adherence to the Task Force methodology were maintained at all stages during review development, the consensus process, and beyond. These were managed by the Task Force Office, under supervision of the Chair, and ensured uniformity and impartiality throughout the review process. The full methodology has previously been described.\textsuperscript{16}

**RESULTS**

**Stroke Risk**

*Chronic Atrial Fibrillation*

Patients with atrial fibrillation are at an increased risk for cerebral embolism. The magnitude of this risk depends upon the cause of the arrhythmia (e.g. mitral stenosis), the age of the patient and associated diagnoses.\textsuperscript{5,8,17,18} Those with non-valvular atrial fibrillation who have not had a stroke have an untreated risk of embolism of between 0% and 8.8% per year. The larger and more recent trials estimate this risk between 2% and 3% per year.\textsuperscript{5,6,18-20} Those with non-valvular atrial fibrillation who have had a stroke show a stroke recurrence rate between 9% and 19% per year and a mortality rate of 9% per year if untreated.\textsuperscript{7,21,22}

*Paroxysmal Atrial Fibrillation*

Paroxysmal atrial fibrillation may be defined as “transient...
Most of the information regarding the paroxysmal atrial fibrillation documented by ECG or Holter at the time of the cerebrovascular event, or in cases of sinus rhythm on baseline ECG, atrial fibrillation documented on ECG or Holter within the previous two years and no successful cardioversion\textsuperscript{1,22}, Dr. P. Koudstaal – personal communication. Unfortunately, many articles on paroxysmal atrial fibrillation do not define the entity as precisely, if at all.

The data on stroke risk with paroxysmal atrial fibrillation are conflicting. Insurance data suggest that paroxysmal atrial fibrillation, in the absence of cardiovascular impairment, shows a normal mortality pattern\textsuperscript{23}. Some studies suggest that primary stroke risk in paroxysmal atrial fibrillation is lower than chronic atrial fibrillation, while others, including recent randomized controlled trials of primary stroke prevention suggest a similar risk\textsuperscript{12,18,24-31}. The best estimate of first stroke in those with paroxysmal atrial fibrillation is approximately 2% per year\textsuperscript{33}. In those with paroxysmal atrial fibrillation, the presence of rheumatic heart disease, increased age, or other cardiac conditions confers an elevated risk for stroke\textsuperscript{33-35}.

There are no published data on the risk of recurrent stroke with paroxysmal atrial fibrillation. However, unpublished data from the European Atrial Fibrillation Trial suggest that the risk of recurrent stroke is similar in those with persistent and paroxysmal atrial fibrillation (20% vs 18%). Dr. P. Koudstaal – personal communication. Although the data are inconclusive, most experts feel that persistent and paroxysmal atrial fibrillation confer similar stroke risks, and recommend equivalent treatment\textsuperscript{5,6,10,12,18,29-32,36,37}.

**Manoeuvre**

The manoeuvre evaluated in this review is the routine use of ambulatory continuous electrocardiography for the detection of paroxysmal atrial fibrillation in patients with stroke whose 12-lead electrocardiogram does not demonstrate atrial fibrillation. An ambulatory continuous electrocardiogram typically records two electrocardiograms leads over a 24- to 48-hour period. Signals can be recorded in a digital or analogue manner. The recorded information is compared with a computer template already classified to detect normal, aberrant supraventricular, or ventricular activity. The investigation is readily available to almost all clinicians\textsuperscript{38} and is a non-invasive test that poses little or no risk to the patient. Reimbursement of professional fees in Canada for interpretation of 24-hour ambulatory electrocardiography range from approximately $29-$60\textsuperscript{39-43}.

There is little information on the sensitivity, specificity, and cost-effectiveness of ambulatory electrocardiography in symptomatic patients\textsuperscript{44}. Most of the information regarding the technology’s ability to detect arrhythmias occurs through analysis of ventricular rather than atrial arrhythmias, which are mostly sought in the evaluation of diagnoses other than stroke. Estimates of ventricular arrhythmia intra- and inter-reader variability can be as high as 10-25% for the same recording if frequent or complex arrhythmias are present\textsuperscript{45}. In contrast, atrial activity is more difficult to detect than ventricular activity due to its smaller amplitude, and may require special analytical techniques for analysis, although findings are conflicting\textsuperscript{44-53}. Thus there may be less agreement on the interpretation of atrial activity although this has never been formally evaluated.

The yield of ambulatory continuous electrocardiography has been studied in cross-sectional studies of consecutive patients presenting to hospital with either a stroke or transient ischemic attack. Atrial fibrillation may be detected on the initial electrocardiogram in 4% to 23% of such patients\textsuperscript{54-60}. In those whose initial electrocardiogram showed normal sinus rhythm, one study found that follow-up 12-lead electrocardiograms on successive days detected atrial fibrillation in an additional 9%\textsuperscript{61}. Other studies have found that if atrial fibrillation is not detected on initial electrocardiogram, ambulatory continuous electrocardiography can identify paroxysmal atrial fibrillation in 1% to 5% of patients (Table 1)\textsuperscript{54-60}. Studies of stroke patients referred for ambulatory continuous electrocardiography, rather than consecutive stroke patients, have identified paroxysmal atrial fibrillation in fewer than 2% of patients\textsuperscript{62-65}. Thus, even in selected cases, the yield of the manoeuvre is quite low.

**Effectiveness of Intervention**

There have been no studies that have evaluated the effectiveness of ambulatory continuous electrocardiography followed by anticoagulation of documented atrial fibrillation in preventing recurrent stroke. Some data suggest that ambulatory

<table>
<thead>
<tr>
<th>Study</th>
<th>Number of patients</th>
<th>Number with atrial fibrillation</th>
<th>Number with paroxysmal atrial fibrillation not detected on initial ECG</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koudstaal et al.\textsuperscript{54}</td>
<td>100</td>
<td>4</td>
<td>1 (1%)</td>
<td>2 patients did not have admission ECG</td>
</tr>
<tr>
<td>Britton et al.\textsuperscript{55}</td>
<td>100</td>
<td>23</td>
<td>2 (2.6%)</td>
<td></td>
</tr>
<tr>
<td>Richardt et al.\textsuperscript{56}</td>
<td>135</td>
<td>16 \textsuperscript{*}</td>
<td>7 (unable to calculate)</td>
<td></td>
</tr>
<tr>
<td>Norris et al.\textsuperscript{57}</td>
<td>312</td>
<td>36</td>
<td>15 (5.4%)</td>
<td>2 patients did not have admission ECG</td>
</tr>
<tr>
<td>Rem et al.\textsuperscript{58}</td>
<td>184</td>
<td>13</td>
<td>4 (2.3%)</td>
<td></td>
</tr>
<tr>
<td>Mikolich et al.\textsuperscript{59}</td>
<td>30</td>
<td>2</td>
<td>1 (3.6%)</td>
<td></td>
</tr>
<tr>
<td>Hornig et al.\textsuperscript{60}</td>
<td>300</td>
<td>33</td>
<td>10 (3.7%)</td>
<td>Consecutive patients but only 87% received Holter testing</td>
</tr>
</tbody>
</table>

\*arrhythmias not only atrial fibrillation

---

Table 1: Consecutive Patients with Stroke or TIA Undergoing Ambulatory Electrocardiography

---

Volume 27, No. 1 – February 2000

Downloaded from https://www.cambridge.org/core. IP address: 54.70.40.11, on 06 Jul 2018 at 17:08:13, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0317167100051933
The larger study included 1007 patients. \[20,30-32,67\] 

Overall, the trial also compared warfarin to aspirin. A recent meta-analysis of the efficacy of aspirin (Level I evidence). However, some propose (Level I evidence).\[32,73\] Further, ambulatory continuous electrocardiography rarely results in a change in management of patients with atrial fibrillation. \[52,66\]

**Effectiveness of Treatment**

The effectiveness of therapy for primary prevention of stroke in atrial fibrillation has been extensively studied. Both aspirin and warfarin have demonstrated benefit in preventing strokes.\[20,30,32,67\] A recent meta-analysis of the efficacy of aspirin compared to placebo found a relative risk reduction of 21% (95% confidence interval, 0.38-0.51/year, p<0.001), with an annual risk of major bleeding incidents of 1.8% (Level I evidence). Overall, warfarin had a relative risk reduction of 64% for major strokes in patients with non-valvular atrial fibrillation (1.4%/year vs. 0.51%/year, p<0.001), and a lower risk of major bleeding complications with warfarin compared to placebo was 66% (hazard ratio 0.34, 95% CIs 0.20-0.57, NNT 12.5) (Level I evidence).\[21\] The larger study included 1007 patients with atrial fibrillation and previous stroke and found the risk reduction for stroke with warfarin compared to placebo was 66% (hazard ratio 0.34, 95% CIs 0.20-0.57, NNT 12.5) (Level I evidence). While the risk of recurrent stroke for those on placebo was 12% per year (compared to 4% per year in the primary prevention trials), the risk of major or minor bleeding complications with warfarin is about 2.8% per year (hazard ratio 2.8, 95% CIs 1.9-6.0). Of note, the target International Normalized Ratio (INR) of 2.5 to 4.0 exceeded recommended levels and was higher than those used in many comparable trials.\[32,73\]

Although about 25% of those in the secondary prevention trials had paroxysmal atrial fibrillation, the data for this subgroup were not presented. Comparable data from a pooled analysis of primary prevention trials found that previous stroke is the strongest predictor of subsequent stroke in those with atrial fibrillation. Further, it detected no difference in stroke risk related to the type of atrial fibrillation.\[5,6,10,12,18,29,32\] Hence it seems reasonable to generalize the efficacy of anticoagulation in secondary prevention of stroke to this group.

**Interpretation**

**Canadian Task Force Recommendations (Table 2)**

The limited available data on the natural history and the effectiveness of treatment for paroxysmal atrial fibrillation precludes the generation of strong recommendations. The diagnosis of atrial fibrillation can frequently be made with a 12-lead electrocardiogram and ambulatory continuous electrocardiography often provides added cost with little added benefit.\[52,66\] Further, ambulatory continuous electrocardiography may not lead to a change in the management of patients who have other indications for anticoagulation. There is insufficient evidence to recommend for or against the use of ambulatory electrocardiography in all patients with stroke (C Recommendation). There is fair evidence to support the use of warfarin therapy for secondary stroke risk reduction in those with paroxysmal atrial fibrillation (B Recommendation based on generalization from data on chronic atrial fibrillation and expert recommendations).

**Recommendations of Others**

The American College of Cardiology/American Heart Association Task Force on the assessment of diagnostic and therapeutic cardiovascular procedures suggests a Class II
indication (“subject to a divergence of opinion with respect to its utility”) for the use of ambulatory electrocardiography in patients with known atrial fibrillation and treated with antiarrhythmic medication. Neither their recommendations nor other reviews mention the use of ambulatory electrocardiography in the evaluation of strokes.

Other authors recommend that ambulatory electrocardiographic monitoring be used in patients with suspected occult arrhythmias but should not be used in the initial evaluation of a stroke patient.

Research Agenda
To fully address the question of the most cost-effective method for stroke investigation, an evaluation of approaches or algorithms for the use and sequencing of tests (i.e. 12-lead electrocardiogram then ambulatory continuous electrocardiography) should be undertaken in consecutive stroke patients after proper hypothesis generating exercises. As well, a formal cost-effectiveness analysis could be performed after many of these questions are addressed. Further research should also compare both the primary and secondary stroke risks in paroxysmal and chronic atrial fibrillation. Subgroup analyses of the two previous secondary prevention trials would help estimate the risk reduction for those with paroxysmal atrial fibrillation.

Members of the Canadian Task Force on Preventive Health Care
Chairman: Dr. John W. Feightner, Professor, Department of Family Medicine, The University of Western Ontario, London, Ont.; Past chairman: Dr. Richard Goldbloom, Professor, Department of Pediatrics, Dalhousie University, Halifax, NS. Members: Drs. R. Wayne Elford, Professor and Chair of Research, Department of Family Medicine, University of Calgary, Calgary, Alta.; Michel Labrecque, Associate Professor and Director of Research, Department of Family Medicine and Centre Hospitalier Universitaire de Quebec, Laval University, Quebec, Que.; Harriet MacMillan, Associate Professor, Departments of Psychiatry & Pediatrics and Centre for Studies of Children at Risk, McMaster University, Hamilton, Ont.; Robin McLeod, Professor, Department of Surgery, Mount Sinai Hospital and University of Toronto, Toronto, Ont.; Jean-Marie Moutquin, Professor, Department of Obstetrics and Gynecology and Research Centre Saint-Francois d’Assise, Laval University, Quebec, Que.; Christopher Patterson, Professor and Head, Division of Geriatric Medicine, Department of Medicine, McMaster University, Hamilton, Ont.; Elaine E.L. Wang, Associate Professor, Departments of Pediatrics and of Public Health Sciences, Faculty of Medicine, University of Toronto, Toronto, Ont. Resource people: Ms. Nadine Wathen, Coordinator, Canadian Task Force on Preventive Health Care, Department of Family Medicine, The University of Western Ontario, London, Ont. and Mr. Tim Pauley, Research Assistant, Canadian Task Force on Preventive Health Care, Department of Family Medicine, The University of Western Ontario, London, Ont.

Acknowledgements
We thank Dr. Bruce Reeder, University of Saskatchewan, Saskatoon, Saskatchewan, and Dr. Andreas Laupacis, Loeb Research Institute, Ottawa, Ontario, for reviewing a draft form of this report. The views expressed in this report are those of the authors and the Task Force and do not necessarily reflect the positions of reviewers.

Support
Dr. Bell holds a Medical Research Council of Canada Research Fellowship. Dr. Kapral held a Research Fellowship from the Heart and Stroke Foundation of Canada at the time of authorship.

References
APPENDIX 1

Canadian Task Force on Preventive Health Care
Levels of Evidence and Grades of Recommendations

Quality of Published Evidence

I Evidence from at least one properly randomized controlled trial (RCT).
II-1 Evidence from well-designed controlled trials without randomization.
II-2 Evidence from well-designed cohort or case-control analytic studies, preferably from more than one centre or research group.
II-3 Evidence from comparisons between times or places with or without the intervention. Dramatic results in uncontrolled experiments could also be included here.
III Opinions of respected authorities, based on clinical experience, descriptive studies or reports of expert committees.

Grades of Recommendations

A Good evidence to support the recommendation that the condition be specifically considered in a periodic health examination (PHE).
B Fair evidence to support the recommendation that the condition be specifically considered in a PHE.
C Insufficient evidence regarding inclusion or exclusion of the condition in a PHE, but recommendations may be made on other grounds.
D Fair evidence to support the recommendation that the condition be specifically excluded from consideration in a PHE.
E Good evidence to support the recommendation that the condition be specifically excluded from consideration in a PHE.